Inivata is a leader in liquid biopsy. Our InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. Our technology is based on pioneering research from the University of Cambridge Our lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmabio companies on InVisionFirst™-Lung and its wider platform, which is applicable to a range of cancer types.